In a report released today, Suraj Kalia from Oppenheimer maintained a Buy rating on TransMedics Group (TMDX – Research Report), with a price target of $92.00. The company’s shares closed yesterday at $40.19.
According to TipRanks, Kalia is a 4-star analyst with an average return of 3.7% and a 50.33% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Shockwave Medical, and TransMedics Group.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for TransMedics Group with a $77.25 average price target, implying a 92.21% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $100.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on TransMedics Group’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $52.47 million and a GAAP net loss of $1 million. In comparison, last year the company earned a revenue of $20.52 million and had a GAAP net loss of $11.52 million
Based on the recent corporate insider activity of 69 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TMDX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TransMedics Group (TMDX) Company Description:
TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.
Read More on TMDX:
